188 related articles for article (PubMed ID: 12883737)
1. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival.
Høgdall EV; Johansen JS; Kjaer SK; Price PA; Christensen L; Blaakaer J; Bock JE; Glud E; Høgdall CK
Oncol Rep; 2003; 10(5):1535-8. PubMed ID: 12883737
[TBL] [Abstract][Full Text] [Related]
2. Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer.
Dehn H; Høgdall EV; Johansen JS; Jørgensen M; Price PA; Engelholm SA; Høgdall CK
Acta Obstet Gynecol Scand; 2003 Mar; 82(3):287-93. PubMed ID: 12694127
[TBL] [Abstract][Full Text] [Related]
3. YKL-40 tissue expression and plasma levels in patients with ovarian cancer.
Høgdall EV; Ringsholt M; Høgdall CK; Christensen IJ; Johansen JS; Kjaer SK; Blaakaer J; Ostenfeld-Møller L; Price PA; Christensen LH
BMC Cancer; 2009 Jan; 9():8. PubMed ID: 19134206
[TBL] [Abstract][Full Text] [Related]
4. Early detection and prognosis of ovarian cancer using serum YKL-40.
Dupont J; Tanwar MK; Thaler HT; Fleisher M; Kauff N; Hensley ML; Sabbatini P; Anderson S; Aghajanian C; Holland EC; Spriggs DR
J Clin Oncol; 2004 Aug; 22(16):3330-9. PubMed ID: 15310777
[TBL] [Abstract][Full Text] [Related]
5. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival.
Cintin C; Johansen JS; Christensen IJ; Price PA; Sørensen S; Nielsen HJ
Cancer; 2002 Jul; 95(2):267-74. PubMed ID: 12124825
[TBL] [Abstract][Full Text] [Related]
6. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival.
Johansen JS; Christensen IJ; Riisbro R; Greenall M; Han C; Price PA; Smith K; Brünner N; Harris AL
Breast Cancer Res Treat; 2003 Jul; 80(1):15-21. PubMed ID: 12889595
[TBL] [Abstract][Full Text] [Related]
7. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
Diefenbach CS; Shah Z; Iasonos A; Barakat RR; Levine DA; Aghajanian C; Sabbatini P; Hensley ML; Konner J; Tew W; Spriggs D; Fleisher M; Thaler H; Dupont J
Gynecol Oncol; 2007 Feb; 104(2):435-42. PubMed ID: 17023034
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
9. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival.
Roslind A; Johansen JS; Christensen IJ; Kiss K; Balslev E; Nielsen DL; Bentzen J; Price PA; Andersen E
Int J Cancer; 2008 Feb; 122(4):857-63. PubMed ID: 17957792
[TBL] [Abstract][Full Text] [Related]
10. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma.
Schmidt H; Johansen JS; Sjoegren P; Christensen IJ; Sorensen BS; Fode K; Larsen J; von der Maase H
J Clin Oncol; 2006 Feb; 24(5):798-804. PubMed ID: 16391295
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H
Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816
[TBL] [Abstract][Full Text] [Related]
12. Serum YKL-40 and colorectal cancer.
Cintin C; Johansen JS; Christensen IJ; Price PA; Sørensen S; Nielsen HJ
Br J Cancer; 1999 Mar; 79(9-10):1494-9. PubMed ID: 10188896
[TBL] [Abstract][Full Text] [Related]
13. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer.
Yamac D; Ozturk B; Coskun U; Tekin E; Sancak B; Yildiz R; Atalay C
Adv Ther; 2008 Aug; 25(8):801-9. PubMed ID: 18670741
[TBL] [Abstract][Full Text] [Related]
14. Elevated serum YKL-40 level predicts poor prognosis in hepatocellular carcinoma after surgery.
Zhu CB; Chen LL; Tian JJ; Su L; Wang C; Gai ZT; Du WJ; Ma GL
Ann Surg Oncol; 2012 Mar; 19(3):817-25. PubMed ID: 21861215
[TBL] [Abstract][Full Text] [Related]
15. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.
Jensen BV; Johansen JS; Price PA
Clin Cancer Res; 2003 Oct; 9(12):4423-34. PubMed ID: 14555515
[TBL] [Abstract][Full Text] [Related]
16. Elevated pretreatment serum concentration of YKL-40-An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer.
Thöm I; Andritzky B; Schuch G; Burkholder I; Edler L; Johansen JS; Bokemeyer C; Schumacher U; Laack E
Cancer; 2010 Sep; 116(17):4114-21. PubMed ID: 20564116
[TBL] [Abstract][Full Text] [Related]
17. High serum YKL-40 level in patients with small cell lung cancer is related to early death.
Johansen JS; Drivsholm L; Price PA; Christensen IJ
Lung Cancer; 2004 Dec; 46(3):333-40. PubMed ID: 15541818
[TBL] [Abstract][Full Text] [Related]
18. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia.
Bergmann OJ; Johansen JS; Klausen TW; Mylin AK; Kristensen JS; Kjeldsen E; Johnsen HE
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8644-52. PubMed ID: 16361549
[TBL] [Abstract][Full Text] [Related]
19. Serum YKL-40 predicts adverse clinical outcomes in patients with chronic heart failure.
Bilim O; Takeishi Y; Kitahara T; Ishino M; Sasaki T; Suzuki S; Shishido T; Kubota I
J Card Fail; 2010 Nov; 16(11):873-9. PubMed ID: 21055651
[TBL] [Abstract][Full Text] [Related]
20. The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab.
Boisen MK; Madsen CV; Dehlendorff C; Jakobsen A; Johansen JS; Steffensen KD
Int J Gynecol Cancer; 2016 Oct; 26(8):1390-8. PubMed ID: 27648712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
